These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Narayanan A; Narwal M; Majowicz SA; Varricchio C; Toner SA; Ballatore C; Brancale A; Murakami KS; Jose J Commun Biol; 2022 Feb; 5(1):169. PubMed ID: 35217718 [TBL] [Abstract][Full Text] [Related]
24. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2. Yassine R; Makrem M; Farhat F Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259 [TBL] [Abstract][Full Text] [Related]
25. Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach. Belhassan A; En-Nahli F; Zaki H; Lakhlifi T; Bouachrine M Life Sci; 2020 Dec; 262():118469. PubMed ID: 32956664 [TBL] [Abstract][Full Text] [Related]
26. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151 [TBL] [Abstract][Full Text] [Related]
27. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19. Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074 [TBL] [Abstract][Full Text] [Related]
29. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum. Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348 [TBL] [Abstract][Full Text] [Related]
30. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists. Zhang S; Krumberger M; Morris MA; Parrocha CMT; Kreutzer AG; Nowick JS Eur J Med Chem; 2021 Jun; 218():113390. PubMed ID: 33812315 [TBL] [Abstract][Full Text] [Related]
32. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug. Isgrò C; Sardanelli AM; Palese LL Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132 [TBL] [Abstract][Full Text] [Related]
33. Phenylbenzopyrone of Flavonoids as a Potential Scaffold to Prevent SARSCoV-2 Replication by Inhibiting its M Potshangbam AM; Nongdam P; Kumar AK; Rathore RS Curr Pharm Biotechnol; 2021; 22(15):2054-2070. PubMed ID: 33504301 [TBL] [Abstract][Full Text] [Related]
34. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity. Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954 [TBL] [Abstract][Full Text] [Related]
35. Merbromin is a mixed-type inhibitor of 3-chyomotrypsin like protease of SARS-CoV-2. Chen J; Zhang Y; Zeng D; Zhang B; Ye X; Zeng Z; Zhang XK; Wang Z; Zhou H Biochem Biophys Res Commun; 2022 Feb; 591():118-123. PubMed ID: 35007835 [TBL] [Abstract][Full Text] [Related]
36. Allergen fragrance molecules: a potential relief for COVID-19. Aydın AD; Altınel F; Erdoğmuş H; Son ÇD BMC Complement Med Ther; 2021 Jan; 21(1):41. PubMed ID: 33478471 [TBL] [Abstract][Full Text] [Related]
37. Apigenin analogues as SARS-CoV-2 main protease inhibitors: Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792 [TBL] [Abstract][Full Text] [Related]
38. In Silico Evaluation of Iranian Medicinal Plant Phytoconstituents as Inhibitors against Main Protease and the Receptor-Binding Domain of SARS-CoV-2. Mousavi SS; Karami A; Haghighi TM; Tumilaar SG; Fatimawali ; Idroes R; Mahmud S; Celik I; Ağagündüz D; Tallei TE; Emran TB; Capasso R Molecules; 2021 Sep; 26(18):. PubMed ID: 34577194 [TBL] [Abstract][Full Text] [Related]
39. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19. Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348 [TBL] [Abstract][Full Text] [Related]
40. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]